Homepage > Company > Media > Pharma News > 2022 > FDA Expands Approval of Bayer’s Nubeqa for Prostate Cancer

FDA Expands Approval of Bayer’s Nubeqa for Prostate Cancer

The FDA has expanded its approval of Bayer’s cancer drug Nubeqa (darolutamide), this time approving the drug in combination with the chemotherapy drug docetaxel for adult patients with metastatic hormone-sensitive prostate cancer.

Nubeqa works by preventing male sex hormones from binding to proteins called androgen receptors, which are found in normal prostate cells and some prostate cancer cells.

The expanded approval was based on study results showing improved overall survival in treated patients. Nubeqa combined with androgen deprivation therapy and docetaxel reduced the risk of death by 32 percent.

The oral drug was first approved in July 2019 for the treatment of adult patients with non-metastatic castration-resistant prostate cancer.

August 9, 2022

https://www.fdanews.com/

Read also

FDA approves AstraZeneca’s FASENRA for asthma in children

The expanded approval of FASENRA for use in younger patients comes after the regulator initially approved the therapy in 2017.

Candel wins FDA orphan drug designation for pancreatic cancer drug

The US Food and Drug Administration (FDA) has granted Candel Therapeutics’ immunotherapy candidate CAN-2409 (aglatimagene besadenovec) orphan drug designation for the treatment of pa...

FDA Gives Fast Track Designation to LYT-200 in Advanced Head and Neck Cancers

LYT-200 is currently being investigated for those with solid tumors and hematologic malignancies.

Vertex to expand autoimmune and inflammatory disease pipeline with $4.9bn Alpine acquisition

Vertex Pharmaceuticals has announced its acquisition of Alpine Immune Sciences, a biotechnology company focused on developing and discovering protein-based immunotherapies, in a deal worth $4.9bn.